Home›Stocks›RARE

RARE — structural market context

Ultragenyx Pharmaceutical Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

RARE short interest & days to cover

SHARES SHORT

15.0M

% OF FLOAT

—

DAYS TO COVER

8.3

CHANGE VS PRIOR

+11.4%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-07-31 (20d ago)

RARE fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-07-30 · 21d	290	$25
2026-07-20 · 31d	188	$29.28
2026-07-17 · 34d	10	$30.22

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

RARE analyst ratings — with each firm's measured accuracy

Firm	Action	Rating	Firm 5d hit rate*	Published
Cantor Fitzgerald	hold	Overweight	42.1% (n=76)	2026-08-20
Canaccord Genuity	price_target	—	n<30	2026-08-20
Wells Fargo	price_target	—	56.9% (n=58)	2026-08-20
Wells Fargo	hold	Overweight	56.9% (n=58)	2026-08-20
Citigroup	hold	Buy	52.5% (n=61)	2026-08-20

*Rating actions from public feeds. Where shown, the firm's 5-day hit rate is our measured backtest (firms with >=30 graded calls); a historical hit rate describes past calls, it does not grade this one.

Frequently asked questions

What do analysts say about RARE?

The most recent action: Cantor Fitzgerald hold to Overweight on 2026-08-20. In our backtest, Cantor Fitzgerald's 5-day hit rate across 76 graded calls is 42.1%. We show each firm's measured record next to its ratings; a historical hit rate describes past calls and does not grade this one.

Is this page telling me to buy or sell RARE?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker Analyst Accuracy tracker The platform

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.